{"id":904002,"date":"2025-11-03T08:26:42","date_gmt":"2025-11-03T13:26:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/"},"modified":"2025-11-03T08:26:42","modified_gmt":"2025-11-03T13:26:42","slug":"abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/","title":{"rendered":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Achieved ~60% reduction in operating costs through a focused cost optimization plan<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>DiversImmune<sup>\u00ae<\/sup> platform positioned to unlock additional pipeline value<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Reverse stock split supports Nasdaq compliance and positions company for next phase of growth<\/em>\n      <\/p>\n<p>BURLINGTON, Mass., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Abpro Holdings, Inc. (Nasdaq: ABP) (\u201cAbpro\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the \u201cReverse Stock Split\u201d) of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company\u2019s common stock will begin trading on a split-adjusted basis at the open of trading on November 3, 2025 under the ticker symbol \u201cABP\u201d and the new CUSIP number will be 000847202<strong>.<\/strong><\/p>\n<p>At the effective time, every 30 shares of issued and outstanding common stock will automatically combine into one (1) issued and outstanding share. No fractional shares will be issued as a result of the Reverse Stock Split; stockholders otherwise entitled to a fractional share will receive an additional fraction rounded up to the next whole share. Following the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 81.2 million to 2.7 million. Shares underlying the Company\u2019s outstanding stock options and warrants will be proportionally adjusted, along with corresponding exercise prices.<\/p>\n<p>The Company\u2019s transfer agent, Continental Stock Transfer &amp; Trust Company, will serve as the exchange agent for the Reverse Stock Split.<\/p>\n<p>\u201cThis action is a highly necessary step in our efforts to maintain our Nasdaq listing and reflects a broader realignment of Abpro for the future,\u201d said Miles Suk, Chief Executive Officer and Chairman of Abpro. \u201cWith a leaner cost structure, a major global partner in Celltrion, and a differentiated antibody platform, we are positioned to execute more effectively and create long-term value for our shareholders.\u201d<\/p>\n<p>\n        <strong><br \/>\n          <em>Positioned for Growth and Value Creation<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>The Reverse Stock Split positions Abpro to reach compliance with Nasdaq as the Company enters a more focused and capital-efficient phase of growth. Over the past few quarters, Abpro has achieved an estimated ~60% reduction in operating costs versus the same period in 2024 through disciplined execution and streamlined operations.<\/p>\n<p>The Company\u2019s partnership with Celltrion remains a key strategic advantage. Celltrion funds all development expenses for Abpro\u2019s lead antibody program ABP-102, while Abpro retains meaningful commercial and economic rights. A first-in-human trial for ABP-102 is anticipated in 2026.<\/p>\n<p>Abpro is also evaluating its broader pipeline to unlock additional value through its <strong>DiversImmune<sup>\u00ae<\/sup><\/strong> and <strong>MultiMab<\/strong><sup><strong>TM<\/strong><\/sup> platforms, which together enable the rapid creation of bispecific and multispecific antibodies with enhanced selectivity and safety.<\/p>\n<p>\n        <strong>About Abpro<\/strong><br \/>\n        <br \/>Abpro\u2019s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro&#8217;s proprietary DiversImmune<sup>\u00ae<\/sup> platform. Abpro is located in Woburn, Massachusetts. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XrUQ2OP8ZFfh_8Tp7CvNh_C1cLD8oWELzAjARucLk2lbtFyNUBiOgMaqYPqH5WmxumhCKwweW0ylAz1N-yOrLyWPaSH6jdeiBWqXxa9_N8Mrue5sii3PnJajnVMCfkt2ObcFUxWLp133d-Jt5hPU_RuS8Syflw3AokHGDc0fQR2Pz4wcYd8JUpdeUNxHZDhbsAADYr8yBiJgxo2PwXGC8b6I0CQ-LHUkoS0R_PxSBhU=\" rel=\"nofollow\" target=\"_blank\">www.abpro.co<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, and expectations regarding the therapeutic benefit of Abpro\u2019s programs, as well as strategic partnerships. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; Abpro\u2019s ability to continue as a going concern; Abpro\u2019s ability to achieve compliance with Nasdaq listing standards; expectations regarding the therapeutic benefit of Abpro\u2019s programs; that final data from Abpro\u2019s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; Abpro\u2019s ability to efficiently discover and develop product candidates; Abpro\u2019s ability to obtain and maintain regulatory approval of product candidates; Abpro\u2019s ability to maintain its intellectual property; the implementation of Abpro\u2019s business model, including strategic plans for Abpro\u2019s business and product candidates; and other risks identified in Abpro\u2019s filings with the U.S. Securities and Exchange Commission (SEC) including Abpro\u2019s most recent Annual Report on Form 10-K filed with the SEC and subsequent filings with the SEC. Abpro cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Abpro disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Abpro\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>Investor and Media Contact: <\/strong><br \/>\n        <br \/>Daniel Kontoh-Boateng<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FGpiN4NJyGn3E5sPK265JYCccV8uBGWE606yhTzAVuZ4Vv-8nfF56R9uAiwzzryDM6AG6jqjr5xrkFi5U0SNGTcLhj8UOCUXXV6RSnpJr8OJsbhCPehWP0Wwiy0pWIfwYl2mi0ltBMjA4WbeKwAbBmWZWqWtSvRzwlFcG8gXFWO1YHRk8-dPAIqhvneNzzdrcYVE0kY3WbX-LLHotzvA2FognQyzyl7pB5uiErnvyxAsK3ofWmBdO5hIGiPdbZg4hDTJMhw5K2_V5kokV53mXg==\" rel=\"nofollow\" target=\"_blank\">DKB Partners, LLC<\/a><br \/>Tel: +1-862-213-1398<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N60xk6pBHkAJx0wv4Zjx8WeG0mzdfY5t1MzElYBMG5ykfSYgvXvSMBeADT3wrDQ7MgENYD9LDocDQCRZrI2ZvqwG9tNWilQPKPAVjdCbbeCRHYJ1yM2CIPM9e85xkmW8FiWp95tu9daHTr06Cmi72e1KyHezMTRQLhpE_NRTjQpEvWNLDIzMWHf7pCtsscMMru8ciflocsojIpQ1vxNSztgDI1mVaRWIyVVAzK8JKybyipFpvL-BeuEndsTr6XDHDJ_v4Rx91CrJSHgb6Ium-QA9_dweJflK2mOLNBgyC2Y=\" rel=\"nofollow\" target=\"_blank\">dboateng@dkbpartners.net<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDg2NTkyNTQtZjFhNy00ZDBhLWIzZDYtMDY3YjYwOTZiNWNiLTExMTA3OTgtMjAyNS0xMS0wMy1lbg==\/tiny\/Abpro-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune\u00ae platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Abpro Holdings, Inc. (Nasdaq: ABP) (\u201cAbpro\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the \u201cReverse Stock Split\u201d) of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company\u2019s common stock will begin trading on a split-adjusted basis at the open of trading on November 3, 2025 under the ticker symbol \u201cABP\u201d and the new CUSIP number will be 000847202. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904002","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune\u00ae platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Abpro Holdings, Inc. (Nasdaq: ABP) (\u201cAbpro\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the \u201cReverse Stock Split\u201d) of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company\u2019s common stock will begin trading on a split-adjusted basis at the open of trading on November 3, 2025 under the ticker symbol \u201cABP\u201d and the new CUSIP number will be 000847202. &hellip; Continue reading &quot;Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:26:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025\",\"datePublished\":\"2025-11-03T13:26:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/\"},\"wordCount\":925,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/\",\"name\":\"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\",\"datePublished\":\"2025-11-03T13:26:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/","og_locale":"en_US","og_type":"article","og_title":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk","og_description":"Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune\u00ae platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance and positions company for next phase of growth BURLINGTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Abpro Holdings, Inc. (Nasdaq: ABP) (\u201cAbpro\u201d or the \u201cCompany\u201d), a biotechnology company advancing next-generation antibody therapies, today announced that its previously approved 1-for-30 reverse stock split (the \u201cReverse Stock Split\u201d) of its common stock became effective at 5:01 p.m. Eastern Time on October 31, 2025. The Company\u2019s common stock will begin trading on a split-adjusted basis at the open of trading on November 3, 2025 under the ticker symbol \u201cABP\u201d and the new CUSIP number will be 000847202. &hellip; Continue reading \"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:26:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025","datePublished":"2025-11-03T13:26:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/"},"wordCount":925,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/","name":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=","datePublished":"2025-11-03T13:26:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzA1OSM3MjM4Nzk0IzIwOTkyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-1-for-30-reverse-stock-split-effective-november-3-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904002"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904002\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}